Meta-Analysis Probes Cancer Risk Concern for JAK Inhibitors
Although no increased cancer risk was seen vs methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than were tumor necrosis factor inhibitors in a meta-analysis.
Medscape Medical News
source https://www.medscape.com/viewarticle/991205?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/991205?src=rss
Comments
Post a Comment